SynthesisPharmacoEconomics - open2026
The Economic and Humanistic Burden of Phenylketonuria Among Patients and Their Caregivers: A Systematic Literature Review.
Synthesis in PharmacoEconomics - open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesPhenylketonuria (PKU) is a rare autosomal recessive metabolic disorder resulting from a deficiency in phenylalanine hydroxylase (PAH) enzyme activity. This systematic literature review (SLR) aims to synthesize the available evidence on the economic and humanistic burden of PKU on patients and their caregivers.
methodsA comprehensive SLR was conducted using PubMed, Embase, Cochrane Library, International Prospective Register of Systematic Reviews (PROSPERO), EconLit, and the Cost-Effectiveness Analysis (CEA) Registry, from database inception to June 2026. Eligible studies were published in English, included individuals diagnosed with PAH deficiency (including PKU) and/or their caregivers, and reported original data on either the economic or humanistic burden of the condition.
resultsOf 2131 records identified, 1330 were screened after deduplication, and 313 underwent full-text review. A total of 130 studies were included, with 44 reporting on economic burden and 87 covering humanistic burden-related outcomes. The economic burden of dietary management was substantial, with mean per patient per year (PPPY) costs ranging from US$1634 to US$35,946, and an estimated 233-359 h PPPY dedicated to diet-related activities. Humanistic burden was also significant; the long-term metabolic control significantly influenced multiple domains of health-related quality of life (HRQoL). In a study involving adults with PKU (n = 88), dietary protein restriction was found to be negatively associated with HRQoL (Rp = 0.265, p < 0.05), and similarly, anxiety was also negatively correlated with blood phenylalanine (Phe) levels (Rs = 0.186-0.209, p < 0.05).
conclusionsFindings underscore the substantial financial, time, and psychological burden of PKU, particularly in relation to dietary management.
Identifiers
42859364What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.